Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study

Ya Hsu Yang, Jen Kou Lin, Wei Shone Chen, Tzu Chen Lin, Shung Haur Yang, Jeng Kai Jiang, Shih Ching Chang, Yuan Tzu Lan, Chun Chi Lin, Chueh Chuan Yen, Cheng Hwai Tzeng, Wei Shu Wang, Huey Ling Chiang, Chung Jen Teng*, Hao Wei Teng

*此作品的通信作者

研究成果: Article同行評審

47 引文 斯高帕斯(Scopus)

摘要

Background This open-label pilot study is aimed to evaluate the efficacy and tolerability of the antidepressant duloxetine, which is effective for diabetic neuropathic pain, in the treatment of chronic oxaliplatin-induced peripheral neuropathy (OIPN). Methods We enrolled a total of 39 patients with stage III or IV colorectal cancer with chronic OIPN. They were treated with duloxetine by increasing the dose from 30 mg/day to 60 mg/ day. Patients' pain intensity was rated at baseline and 12 weeks after duloxetine administration. The severity of neuropathic pain was evaluated using the visual analog scale (VAS) score and the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3 (NCI-CTCAE v3.0). Results Nine patients (23.1%) discontinued duloxetine before the end of treatment because of adverse events. Of the remaining 30 patients, 19 patients (63.3%) had a VAS score improvement. Among them, nine (47.4%) showed a simultaneous grade improvement, and the other 10 patients (52.6%) had a stable grade according to NCI-CTCAE v3.0. Treatment with duloxetine did not impair renal or liver function and did not interfere with chemotherapy. Conclusions Duloxetine is feasible in treating chronic OIPN with tolerable toxicity at a daily dose of 60 mg/day.

原文English
頁(從 - 到)1491-1497
頁數7
期刊Supportive Care in Cancer
20
發行號7
DOIs
出版狀態Published - 7月 2012

指紋

深入研究「Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study」主題。共同形成了獨特的指紋。

引用此